REGENERON PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
REGN$916.06-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)
(In millions)
| Class A Stock · Common Stock · AdditionalPaid-in Capital · Retained Earnings · Accumulated Other Comprehensive Income (Loss) · Treasury Stock · Total Stockholders' Equity | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||||||||||||||||
| Balance, December 31, 2023 | 1.8 | $— | 133.1 | $0.1 | $11,354.0 | $27,260.3 | $(80.9) | (25.5) | $(12,560.4) | $25,973.1 | ||||||||||||||
| Issuance of Common Stock for equity awards granted under long-term incentive plans | — | — | 1.5 | — | 672.4 | — | — | — | — | 672.4 | ||||||||||||||
| Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations | — | — | (0.4) | — | (335.9) | — | — | — | — | (335.9) | ||||||||||||||
| Issuance/distribution of Common Stock for 401(k) Savings Plan | — | — | — | — | 18.8 | — | — | — | 1.7 | 20.5 | ||||||||||||||
| Repurchases of Common Stock | — | — | — | — | — | — | — | (0.3) | (298.0) | (298.0) | ||||||||||||||
| Stock-based compensation charges | — | — | — | — | 233.3 | — | — | — | — | 233.3 | ||||||||||||||
| Net income | — | — | — | — | — | 722.0 | — | — | — | 722.0 | ||||||||||||||
| Other comprehensive income, net of tax | — | — | — | — | — | — | 3.7 | — | — | 3.7 | ||||||||||||||
| Balance, March 31, 2024 | 1.8 | $— | 134.2 | $0.1 | $11,942.6 | $27,982.3 | $(77.2) | (25.8) | $(12,856.7) | $26,991.1 | ||||||||||||||
| Balance, December 31, 2022 | 1.8 | $— | 130.4 | $0.1 | $9,949.3 | $23,306.7 | $(238.8) | (22.6) | $(10,353.3) | $22,664.0 | ||||||||||||||
| Issuance of Common Stock for equity awards granted under long-term incentive plans | — | — | 1.1 | — | 491.3 | — | — | — | — | 491.3 | ||||||||||||||
| Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations | — | — | (0.1) | — | (99.2) | — | — | — | — | (99.2) | ||||||||||||||
| Issuance/distribution of Common Stock for 401(k) Savings Plan | — | — | — | — | 18.9 | — | — | — | 1.7 | 20.6 | ||||||||||||||
| Repurchases of Common Stock | — | — | — | — | — | — | — | (0.9) | (693.9) | (693.9) | ||||||||||||||
| Stock-based compensation charges | — | — | — | — | 237.4 | — | — | — | — | 237.4 | ||||||||||||||
| Net income | — | — | — | — | — | 817.8 | — | — | — | 817.8 | ||||||||||||||
| Other comprehensive income, net of tax | — | — | — | — | — | — | 57.2 | — | — | 57.2 | ||||||||||||||
| Balance, March 31, 2023 | 1.8 | $— | 131.4 | $0.1 | $10,597.7 | $24,124.5 | $(181.6) | (23.5) | $(11,045.5) | $23,495.2 | ||||||||||||||
| The accompanying notes are an integral part of the financial statements. | ||||||||||||||||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.